0000899243-20-030470.txt : 20201105
0000899243-20-030470.hdr.sgml : 20201105
20201105161755
ACCESSION NUMBER: 0000899243-20-030470
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201103
FILED AS OF DATE: 20201105
DATE AS OF CHANGE: 20201105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUEHL DANIEL W
CENTRAL INDEX KEY: 0001283569
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 201290690
MAIL ADDRESS:
STREET 1: 5 BILLERICA PARK
STREET 2: 101 BILLERICA AVE
CITY: NORTH BILLERCA
STATE: MA
ZIP: 01862
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-03
0
0001466301
Clovis Oncology, Inc.
CLVS
0001283569
MUEHL DANIEL W
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
2020-11-03
4
M
0
2556
A
33630
D
Common Stock
2020-11-03
4
S
0
1152
4.93
D
32478
D
Common Stock
2020-11-03
4
M
0
3067
A
35545
D
Common Stock
2020-11-03
4
S
0
1382
4.93
D
34163
D
Restricted Stock Units
2020-11-03
4
M
0
5623
0.00
D
Common Stock
5623
50615
D
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
On February 1, 2019, the reporting person was granted 89,982 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Executive Vice President and Chief Financial Officer
/s/ Daniel Muehl
2020-11-05